Compare Adobe Systems Inc (ADBE) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adobe Systems Inc vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Adobe Systems Inc trades at $221.63 (market cap $88.06B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $282.67 (market cap $7.85B). The key difference: Adobe Systems Inc is far larger — about 11.2× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Adobe Systems Inc nearer its low. Which is the better fit depends on your goals.
| ADBE | BIO | |
|---|---|---|
Market Cap | $88.06B | $7.85B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $382.24 | $339.75 |
52-Week Low | $193.41 | $241.71 |
Enterprise Value | $89.50B | $7.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe Inc. (ADBE) trades at $221.01, up 1.35% on the day, with strong fundamentals including a P/E of 12.67 and net income margin of 28.69%. Recent earnings beats in Q3 2025 through Q1 2026 highlight operational strength, while technical indicators show a bullish overall signal despite some overbought RSI readings. The stock faces headwinds from AI competition concerns and a recent 52-week low, but institutional buying activity and a consensus price target of $246.75 suggest underlying confidence.
The outlook for ADBE is cautiously optimistic, with revenue growth and robust cash flow supporting valuation, but investor sentiment is mixed due to AI disruption fears and CEO transition. Near-term resistance at $224 and support at $218 will be key for price direction, with earnings execution and competitive response to AI being critical catalysts.
BIO trades at $292.50, down 1.47% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $2.58B for 2025 with net income of $759.90M, though it missed EPS estimates for three consecutive quarters. Positive cash flow from operations of $532.20M supports financial health, while recent news highlights Nasdaq compliance and industry participation.
Outlook remains cautiously optimistic with a consensus price target of $305.00, representing ~4% upside. Risks include consistent earnings misses and high P/E of 49.11, but strong analyst buy sentiment (53.85%) and improving profitability margins offer potential for recovery if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
